Biofrontera (NASDAQ:BFRI) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of Biofrontera (NASDAQ:BFRI) from a buy rating to a hold rating in a research note released on Sunday,Wall Street Zen reports.

Several other equities research analysts have also weighed in on BFRI. Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Zacks Research raised Biofrontera from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold”.

Biofrontera Stock Performance

NASDAQ:BFRI opened at $1.17 on Friday. The company has a 50-day moving average of $1.31 and a 200-day moving average of $1.09. The firm has a market cap of $17.37 million, a price-to-earnings ratio of -2.60 and a beta of 0.83. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.78. Biofrontera has a twelve month low of $0.55 and a twelve month high of $1.66.

Biofrontera (NASDAQ:BFRI) last released its earnings results on Thursday, August 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The business had revenue of $12.00 million for the quarter, compared to the consensus estimate of $9.50 million. Analysts forecast that Biofrontera will post -0.6 earnings per share for the current fiscal year.

Biofrontera Company Profile

Biofrontera Inc (NASDAQ:BFRI) is a commercial-stage biopharmaceutical company focused on dermatology. The company develops and markets prescription therapies for the treatment of skin conditions, with an emphasis on products that address actinic keratosis and other dermatologic diseases.

Its principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, which is used in combination with the BF-RhodoLED lamp in photodynamic therapy for actinic keratoses. Biofrontera also provides the BF-RhodoLED photodynamic therapy lamp system used by healthcare professionals to activate the treatment.

Biofrontera Inc is based in the United States and operates as part of the broader Biofrontera corporate group, which has German roots and an international dermatology business.